NEULANDLAB2022-01-012022-03-31in-bse-fin:OneOperatingExpenses01Member NEULANDLAB2022-01-012022-03-31in-bse-fin:OneOperatingExpenses02Member NEULANDLAB2022-01-012022-03-31in-bse-fin:FourOperatingExpenses01Member NEULANDLAB2022-01-012022-03-31in-bse-fin:FourOperatingExpenses02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares NEULANDLAB 2021-04-01 2022-03-31 2022-04-18 INR Lakhs Yearly true Cash Flow Indirect Single segment Manufacturing of Active Pharmaceuticals 2022-01-01 2022-03-31 Audited Standalone 2558725000.00 6314000.00 2565039000.00 977133000.00 0.00 198942000.00 424357000.00 27700000.00 124523000.00 571167000.00 2323822000.00 241217000.00 0.00 241217000.00 70304000.00 -47352000.00 22952000.00 0.00 218265000.00 0.00 0.00 0.00 0.00 218265000.00 -18612000.00 199653000.00 0.00 0.00 129005000.00 10 17.01 17.01 0.00 0.00 17.01 17.01 1 The financial results for the quarter and year ended 31 March 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 May 2022. 2 The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3 The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 Operating Segments . 4 The EPS for quarters has not been annualised. 5 The Board of Directors has recommended a dividend of Rs.5.00/- only per equity share of face value of Rs.10 each, for the year ended 31st March, 2022. 6 The figure for the quarter ended 31st March, 2022 & 31st March, 2021 are the balancing figures between the audited figures in respect of the full financial year and the published figures upto nine months of the relevant financial year. 7 The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period. Single segment 2021-04-01 2022-03-31 Audited Standalone 9510766000.00 20767000.00 9531533000.00 4375536000.00 0.00 -154147000.00 1757585000.00 134944000.00 490364000.00 2109853000.00 8714135000.00 817398000.00 0.00 817398000.00 204219000.00 -22155000.00 182064000.00 0.00 635334000.00 0.00 0.00 0.00 0.00 635334000.00 -59917000.00 575417000.00 0.00 0.00 129005000.00 10 0.00 49.52 49.52 0.00 0.00 49.52 49.52 Manufacturing 323632000.00 Others 247535000.00 Manufacturing 1313631000.00 Others 796222000.00 0.00 -176024000.00 -171001000.00 0.00 177276000.00 0.00 0.00 -7066000.00 0.00 -390613000.00 0.00 -24947000.00 0.00 490364000.00 0.00 5234000.00 0.00 -77498000.00 0.00 23119000.00 0.00 9949000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -161105000.00 656293000.00 0.00 -134944000.00 0.00 205262000.00 0.00 585975000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4361000.00 958868000.00 0.00 10148000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10877000.00 0.00 16606000.00 0.00 -937172000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 799222000.00 222607000.00 0.00 25320000.00 38490000.00 135583000.00 0.00 0.00 377222000.00 26025000.00 0.00 26025000.00 11159000.00 37184000.00